Q3 FY2026 · ended Sep 30, 2026 · Revenue $25.60M, +76.6% YoY · Filed Nov 4, 2026
Personalis, Inc. (PSNL) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $25.6 million and a net loss of $33.8 million. Free cash flow was -$30.1 million. As of Sep 30, 2026 it held $190.6 million in cash and investments and $36.3 million in total debt.
Revenue
$25.60M
+76.6% vs year-ago quarter
Net income
$-33.80M
-56.1% vs year-ago quarter
Operating cash flow
$-27.07M
-24.2% vs year-ago quarter
Free cash flow
$-30.14M
-28.7% vs year-ago quarter
EPS
$-0.32
-33.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
108.40M
+22.1% vs year-ago quarter
Net cash
$154.32M
Q3 FY2026
Operating margin
-156.7%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- PSNL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fremont, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1527753
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $25.6M | $22.4M | $15.5M | $17.3M | $14.5M |
| Operating income | -$35.5M | -$33.6M | -$32.2M | -$25.3M | -$23.3M |
| Net income | -$33.8M | -$31.7M | -$30.0M | -$23.8M | -$21.7M |
| Diluted EPS | -$0.32 | -$0.30 | -$0.29 | -$0.26 | -$0.24 |
| Operating cash flow | -$27.1M | -$25.8M | -$22.5M | -$22.2M | -$21.8M |
| Free cash flow | -$30.1M | -$29.6M | -$25.7M | -$22.3M | -$23.4M |
| Total assets | $291.6M | $312.1M | $325.4M | $334.2M | $242.8M |
| Total liabilities | $78.9M | $77.0M | $70.6M | $73.0M | $71.4M |
| Stockholders' equity | $212.7M | $235.2M | $254.8M | $261.2M | $171.4M |
| Cash and investments | $190.6M | $212.7M | $233.2M | $240.0M | $150.5M |
| Total debt | $36.3M | $37.1M | $39.0M | $42.0M | $42.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Other events
|
Aug 20, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
All 556 Personalis, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.